OptiNose, Inc. is a pharmaceutical company with a keen focus on developing and commercializing products exclusively for patients receiving treatment by ear, nose, throat, and allergy specialists in the US. Its proprietary exhalation delivery system (EDS), XHANCE, is designed to deliver a corticosteroid acting topically in treating chronic rhinosinusitis with nasal polyps. OptiNose is also in a Phase IIIb clinical trial for the treatment of chronic sinusitis. Another product in its portfolio is Onzetra Xsail, which is a powder EDS device. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail, besides partnering with Orexia Therapeutics to develop, manufacture, import, and sell products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. Established in 2000, OptiNose is headquartered in Yardley, Pennsylvania.